Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up

Fennec Pharmaceuticals Inc. (FENC) announced that it has entered into an exclusive licensing deal with Norgine, a European specialist pharmaceutical company, to develop and commercialize its only marketed product, Pedmark/Pedmarqsi (sodium thiosulfate injection), in EU, Australia and New Zealand.Fennec initially received FDA approval for Pedmark in 2022, granting marketing permission in the U.S. market as the first and only treatment to reduce the risk of ototoxicity (hearing loss) associated with cisplatin ...